Authors


Beth Faiman, PhD, MSN, APN-BC

Latest:

Key Takeaways on Evolving Treatment Landscape in Multiple Myeloma

The expert panel provides closing remarks on exciting developments in the evolving treatment landscape in multiple myeloma.


Brandon Sheffield, MD

Latest:

Brandon Sheffield, MD, Details NGS Benefits Vs Single-Gene Testing in NSCLC

At the 2022 WCLC, Brandon Sheffield, MD, presented data demonstrating the advantage of next-generation sequencing over other biomarker testing strategies in patients with non–small cell lung cancer.



Arun Nagarajan, MD

Latest:

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.


Apar Kishor Ganti, MD

Latest:

Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung Cancer

Original research published in the journal ONCOLOGY® explored the impacts of treatment refusal in patients with small cell lung cancer.



Liwei Jia, MD, PhD

Latest:

Management of Testicular Germ Cell Tumor With Somatic-Type Malignancy

In this installment of Clinical Quandaries, Bendu Konneh, BS, and colleagues present a case of a 21-year-old male with a 4-month history of progressive swelling in the right testicle.



Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center

Latest:

Value of Collaboration in Managing Patients With Metastatic RCC

Closing out their discussion on the management of metastatic renal cell carcinoma, panelists highlight the value of collaborative care in improving patient outcomes.



Alex Biese

Latest:

Discerning the Best Frontline, Personalized Treatment in Urothelial Carcinoma

“How do we personalize and improve patient selection for frontline treatment now that patients are living, on average, more than 2 years with this aggressive cancer?” said David H. Aggen, MD, PhD


Yoon-Koo Kang, MD, PhD

Latest:

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.


Kanika G. Nair, MD

Latest:

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.


Peter Humphrey MD, PhD

Latest:

Peter Humphrey, MD, PhD, Discusses Current Role of Pathology in RCC

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about the role of pathology in renal cell carcinoma.


Saad Z. Usmani, MD, MBA, FACP

Latest:

Strategies for Community Adoption of Bispecifics into Treatment of Relapsed/ Refractory Multiple Myeloma

Panelists discuss effective strategies for promoting the adoption of bispecific antibodies in relapsed/refractory multiple myeloma (R/R MM) treatment, emphasizing the importance of educational initiatives, improving care transitions between academic and community settings, addressing misconceptions, and sharing key takeaways and clinical pearls for community oncologists.



Noah S. Kalman, MD, MBA

Latest:

Taste Change Data May Inform Radiotherapy Strategy in Head and Neck Cancer

Findings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.




Adrienne Waks, MD

Latest:

HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in Care

Closing out their review of the HER2+ metastatic breast cancer treatment landscape, expert oncologists look forward to future evolutions in the paradigm.


Maria-Victoria Mateos, MD, PhD

Latest:

Closing Thoughts on Bispecific Antibodies and the Future of R/R MM Treatment

The panel looks to the future of relapsed/refractory multiple myeloma treatment and the remaining unmet needs for patients.




Sarah M. Tolaney, MD, MPH

Latest:

Factors in Selecting Therapy for HER2+ Metastatic Breast Cancer With CNS Disease

Shared consideration on the factors that dictate selection of optimal therapy for patients with HER2+ breast cancer and brain metastases.


Fareed Khawaja, MBBS

Latest:

Oncology On-The-Go Podcast: COVID-19 Vaccination and Cellular Therapy in Cancer

Fareed Khawaja, MBBS, and Marilyne Daher, MD discuss COVID-19 vaccine efficacy and safety among patients with cancer in the United States.



Neel Talwar, MD

Latest:

Looking Ahead in the Multiple Myeloma Treatment Landscape

Experts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.


Faith Abodunrin, MD

Latest:

Face-Off: Award Presentation Ceremony

Following a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.


Christopher Lieu, MD

Latest:

MRD and Decision-Making in Early-Stage Colorectal Cancer

This article reviews MRD and decision-making in early-stage colorectal cancer and includes insights from Christopher Lieu, MD, of the University of Colorado School of Medicine in Denver, and Daniel Ahn, DO, of the Mayo Clinic in Phoenix, AZ.


Elizabeth Travers, PharmD, BCOP

Latest:

Expert Commentary on the Product Profile of Asciminib

In an interview with ONCOLOGY®, Elizabeth Travers, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of asciminib as therapy for patients with chronic myeloid leukemia.